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Purpose. This study was performed to measure the concentration of trans-resveratrol and its three metabolites in human eyes.
Methods. The patients who underwent pars plana vitrectomy for rhegmatogenous retinal detachment were included. The
participants were orally given trans-resveratrol-based supplement (Longevinex®). A suitable amount of conjunctiva, aqueous
humor, and vitreous humor were obtained during the operation. High-performance liquid chromatography (HPLC) with
mass spectrometry (LC/MS/MS) was used to detect the concentration of trans-resveratrol and its three metabolites in the
various samples. Results. The average concentration of resveratrol in the conjunctiva was 17.19± 15.32 nmol/g (mean± SD).
The concentration of resveratrol in the aqueous humor was close to the limit of detection, but its metabolites could be
quantified. The concentrations of resveratrol metabolites in the aqueous humor can be detected. In the vitreous humor, the
average concentration of resveratrol-3-O-sulfate was 62.95± 41.97 nmol/L. The sulfate conjugations of resveratrol were
recovered in the conjunctiva, aqueous humor, and vitreous humor. Conclusions. Resveratrol and its three metabolites can be
detected in the ocular tissues after oral administration. Although the concentration of parent resveratrol was low in the
eyes, its metabolites could be detected and may have a role in the treatment of ocular diseases.
1. Introduction
Resveratrol (3,4′,5-trihydroxystilbene) is a natural polyphe-
nolic phytoalexin that is mainly found in grapes, leading to
its high concentration in wine [1]. Additional sources include
peanuts and cranberries [2]. Resveratrol has a stilbene struc-
ture, and the compound consists of two aromatic rings
connected by a methylene bridge [3] (Figure 1). Interest has
arisen due to its cardioprotective action on the vasculature,
especially its ability to inhibit angiogenesis and to facilitate
vasorelaxation [4]. Resveratrol has been suggested to promote
health in dry eye, glaucoma, cataracts, age-related macular
degeneration (AMD), and diabetic retinopathy (DR). Res-
veratrol increases blood perfusion, has anti-inflammatory
effects, and reduces oxidative stress and angiogenesis [3].
However, it has been unclear whether it can reach the
posterior segment of the eye.
Studies performed on rats have shown that resveratrol is
rapidly metabolized in the gut prior to entering the systemic
circulation [5, 6]. The reduced concentration of resveratrol
entering the systemic circulation is compounded further
by recirculation between the small intestine and the liver.
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Metabolism occurs so rapidly that a conjugate of resveratrol
has been detected by high-performance liquid chromato-
graphy (HPLC) less than 10 minutes following intravenous
infusion in human subjects [7]. It has been hypothesized,
however, that despite the fact that the trans-resveratrol
glucuronides have been shown to be inactive in vitro, they
may be active in vivo, and the sulfate conjugate serves as
an inactive pool for resveratrol [8, 9]. Prior studies have
assessed the concentration of resveratrol in animal and
human plasma [10–13]. However, an understanding of the
concentration of resveratrol in tissues, especially in human
eyes, is lacking. Several studies have reported the pharma-
cokinetics and tissue distribution of resveratrol in the liver,
kidneys, lungs, and heart [14, 15]. These studies were mostly
based on animal models; few researchers have used human
subjects for experimentation.
The aim of the present study was to investigate the
tissue distribution of parent resveratrol and its main three
metabolites in human eyes after oral administration. This
study also provides information about the activity of the
metabolites [8].
2. Materials and Methods
2.1. Patients. The eligible participants were inpatients
undergoing pars plana vitrectomy with retinal detachment
repair at Tongji Hospital, Tongji Medical College. Their
health status was determined by an interview, medical
history, physical examination, 12-lead electrocardiogram
(ECG), and clinical laboratory testing. All participants also
underwent a detailed ophthalmic examination, including
best-corrected visual acuity (BCVA) (LogMAR), intraocu-
lar pressure (IOP), and fundus examination. All of the
eyes had been diagnosed just before being consented with
a rhegmatogenous retinal detachment. There were no
obvious vitreous cavities and no anterior chamber bleed-
ing. Female subjects who were pregnant, patients with
anemia, and those who had taken any medication within
one week prior to admission were excluded from partici-
pation. Alcohol and cigarettes were forbidden from 48
hours before admission until discharge from the clinic.
The participants were advised to avoid consumption of
coffee, tea, or cocoa-containing foods during the study. No
foods rich in resveratrol (e.g., grapes, peanuts, and their
products) were allowed until discharge.
The study protocol was approved by the Huazhong
University of Science and Technology Institutional Review
Board and Ethics Committee. The study was conducted
according to the principles of the Declaration of Helsinki,
and all participants gave their written, informed consent
prior to participation. This study is registered at Clinical
Trials.gov (registration number: NCT02321176; registration
date: July 2014).
2.2. Intervention. Longevinex (Resveratrol Partners LLC,
Las Vegas, NV), a nutritional supplement, has 100mg of
trans-resveratrol (purity 85–92%). The micro-sized powder
also contains stabilized 25mg quercetin (purity 98%),
75mg rice bran (70% extract IP6, 30% calcium phytate),
vitamin D3 (1000 IU), and 10mg nucleotides (for DNA
repair). trans-Resveratrol is the active form of resveratrol.
The other four substances have a synergy function in
mediating the bioavailability of resveratrol. Micronization
enfolded in plant starches and dextrins to protect from
light, heat, and oxygen exposure. This blend has been
demonstrated to obtain synergism in studies conducted
at two academic centers and the National Institutes of
Health in the United States [16]. Each of the participants
was given one capsule orally daily for a total of three
doses prior to tissue collection. The capsules were taken
in the morning between 6:00 a.m. and 7:00 a.m. The last dose
was administered in the morning before surgical resection.
2.3. Sample Preparation. The surgical resection was per-
formed approximately 2–4 hours after the final dose of
resveratrol. The conjunctivas were collected, placed on
ice, and protected from light. Frozen tissue samples were
mixed with liquid nitrogen and ground, then weighed and
homogenized with methanol. The samples were then snap-
frozen and kept at −80°C until analysis. Aqueous humor
and vitreous humor were collected in dry EP tubes at the time
of resection. The tubes were chilled on ice, protected from
light, and stored at −80°C until analysis, which was per-
formed within 6 months. We get the tissue sample weight
or volume: conjunctiva (2.8mg–13.7mg), aqueous humor
(50μL–100μL), and vitreous humor (about 200μL).
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Figure 1: (a) Chemical structure of trans-resveratrol. (b) The structure of the metabolites of resveratrol: (1) R1 = sulfate, R2 =H: resveratrol-3-
O-sulfate, (2) R1 =H, R2 = glucuronide: resveratrol-4′-O-glucuronide, and (3) R1 = glucuronide, R2 =H: resveratrol-3-O-glucuronide.
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Venous blood was collected in lithium heparin tubes at
the time of resection (about 2 hours after the final dose of
resveratrol). Tubes were chilled on ice and protected from
light. Plasma was kept at −80°C until analysis, which was also
performed within 6 months. The volume of the blood
withdrawn was about 2mL.
2.4. Analysis of Resveratrol and Its Metabolites. All of the
samples were extracted with a precipitant (methanol : aceto-
nitrile = 1 : 1), then vortexed for 1min. Liquid samples were
centrifuged (3000×g, 4°C, 15min). The supernatant was
removed and analyzed by liquid chromatography tandem
mass spectrometry (LC/MS/MS) with multiple reaction
monitoring (MRM), operated in the negative ion mode as
described previously [17]. The chromatographic column
was aWelchUltimate (2.1mm× 50mm, 5μm), and the guard
column was a Phenomenex C18 (4mm× 3.0mm, 5μm). The
parent resveratrol and metabolites were separated by using
the mobile phase consisting of acetonitrile containing
0.1% methanoic acid and pure water with a flow rate of
0.3mL/min. The quantitation of resveratrol and its three
metabolites using a gradient HPLC system (Shimadzu, LC–
30AT) coupled with MS/MS system (ABsciex Qtrap4500)
was performed using standard materials and a method that
had previously been validated in terms of interday and
intraday variability, recovery, accuracy, and precision [17].
The limit of quantitation was 5 ng/mL, whereas the limit of
detection was half of these values. The resveratrol and its
metabolites in biomatrices were stable under the storage
and assay conditions. The standard material of the parent
resveratrol, resveratrol-3-O-sulfate, resveratrol-3-O-glucuro-
nide, and resveratrol-4′-O-glucuronide were provided by
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
The internal standard was carbamazepine. All of the samples
were extracted and analyzed in duplicate, and the mean
value was used. The statistical analysis was performed by
using SPSS 16.0. All the variables were demonstrated as
arithmetic means.
3. Results
3.1. Characteristics of the Participants. 20 men and 15
women, with a mean age of 51.17± 14.53 years (range 20–
74 years), were included. There were a total of 35 eyes
(left/right = 19/16). The mean intraocular pressure was
11.89± 2.87mmHg (range 5.0–20mmHg). The BCVA (Log-
MAR) in the study group was in the range of LP–1.3
(Table 1).
3.2. Identification of Resveratrol and Its Metabolites in Eye
Tissues. Resveratrol and its metabolites were recovered from
human eye tissues and identified by HPLC/MS/MS analysis
with authentic reference material. Figure 2 shows three
groups of representative HPLC data from the tissue extracts
of three patients who had ingested three doses of resveratrol,
compared with chromatograms from three patients who
did not receive the experimental capsule and had no detect-
able resveratrol or its metabolites. We have detected the
blood of three patients of the participants. And the parent
resveratrol and its metabolites could be quantified
(Figure 3). Identity was confirmed by suitable MRM mass
transitions of mass-to-charge ratios (m/z). The following
species could be identified by mass spectrometry (Figure 4):
trans-resveratrol (m/z: 227/185), resveratrol-3-O-glucuro-
nide (m/z: 403/227), resveratrol-4′-O-glucuronide (m/z:
403/227), resveratrol-3-O-sulfate (m/z: 307/227), and car-
bamazepine (m/z: 283/268).
3.3. Concentrations of Resveratrol and Its Metabolites in Eye
Tissues. The parent resveratrol and its three metabolites were
quantitated in the participants’ eye tissues (Table 2). In most
tissues, the concentrations of resveratrol’s metabolic con-
jugates were higher than those of the parent resveratrol.
Resveratrol or its metabolites was not detected in 10 out of
35 eyes. In at least the conjunctival samples of 25 eyes, we
could detect resveratrol or its metabolites. The concentra-
tions of resveratrol and its metabolites demonstrated inter-
and intraindividual variability. In the conjunctiva, the parent
resveratrol metabolites were quantified in some samples and
eight samples were quantified for the parent resveratrol. The
mean concentration was 17.19± 15.32 nmol/g. The mean
tissue concentrations determined for resveratrol metabolites
were 2.32± 2.00 nmol/g for resveratrol-3-O-glucuronide in
eight samples, 2.12± 2.09 nmol/g for resveratrol-4′-O-glu-
curonide in nine samples, and 22.31± 24.18 nmol/g for
resveratrol-3-O-sulfate in 17 samples. In the aqueous humor,
the peak of the parent resveratrol was very low and the
signal-to-noise ratio (SNR) was <3, but the retention time
of the parent resveratrol in the samples conformed to the
retention time of its standard curve. Therefore, we assumed
that there was a slight amount of the parent resveratrol in
the aqueous humor. The three major metabolites could
also be quantified in the aqueous humor, with mean
concentrations of resveratrol-3-O-glucuronide, resveratrol-
4′-O-glucuronide, and resveratrol-3-O-sulfate of 86.11±
30.76 nmol/L (n = 3), 85.17± 56.73 nmol/L (n = 4), and
364.9± 523.94 nmol/L (n = 7), respectively. In the vitreous
humor, we only quantified resveratrol-3-O-sulfate, which
had a mean concentration of 62.95± 41.97 nmol/L (n = 6).
The SNRs of the parent resveratrol, resveratrol-3-O-glucu-
ronide, and resveratrol-4′-O-glucuronide were <3, so their
true values were below the limit of detection. However, all
Table 1: Characteristics of patients who were recruited into
the study.
Parameters Mean± SD or N (%)
Number of patients 35
ECG Normal
CLT Normal
Age (and range; years) 51.17± 14.53 (20–74)
Gender (males/females) 20 : 15
Eyes (left/right) 19 : 16
IOP (and range; mmHg) 11.89± 2.87 (5.0–20)
BCVA (LogMAR, range) LP–1.3
ECG: 12-lead electrocardiogram; CLT: clinical laboratory test results; BCVA:
best-corrected visual acuity; IOP: intraocular pressure.
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Figure 2: Continued.
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Figure 2: Continued.
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Figure 2: (A1) LC-MS chromatography of the aqueous humor of one patient who did not receive oral resveratrol. (A2) LC-MS
chromatography of standard solution of resveratrol, its major three metabolites, and carbamazepine (internal standard). (A3) LC-MS
chromatography of the aqueous humor of one patient who had taken one capsule daily for three days before tissue extraction. (B1) LC-
MS chromatography of the vitreous humor of one patient who did not receive oral resveratrol. (B2) LC-MS chromatography of standard
solution of resveratrol, its three major metabolites, and carbamazepine (internal standard). (B3) LC-MS chromatography of the vitreous
humor of one patient who had taken one capsule daily for three days before tissue extraction. (C1) LC-MS chromatography of the
conjunctiva of one patient who did not receive oral resveratrol. (C2) LC-MS chromatography of standard solution of resveratrol, its three
major metabolites, and carbamazepine (internal standard). (C3) LC-MS chromatography of the conjunctiva of one patient who had taken
one capsule daily for three days. 1: resveratrol-4′-O-glucuronide; 2: resveratrol-3-O-glucuronide; 3: resveratrol; 4: resveratrol-3-O-sulfate;
and 5: carbamazepine.
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of the retention times of the materials conformed to their
standard carves, indicating that there was also a slight
amount of the parent resveratrol-3-O-glucuronide and res-
veratrol-4′-O-glucuronide in the vitreous humor.
3.4. Concentrations of Resveratrol and Its Metabolites in
Plasma. Plasma was obtained from three patients of the
participants at the point of surgery and analyzed by LC/
MS/MS. Resveratrol and its metabolites were at quantifiable
concentrations (Table 3). The highest level (1969.5 nmol/L)
was observed for resveratrol-3-O-sulfate in the three patients.
4. Discussion
This study is the first to detect resveratrol and its three
metabolites in human eyes after oral administration of this
compound. Longevinex showed synergistic effects of these
compounds. Schlachterman et al. [18] reported a combination
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Figure 3: (D1) LC-MS chromatography of the serum of one patient who did not receive oral resveratrol. (D2) LC-MS chromatography of
standard solution of resveratrol, its major three metabolites, and carbamazepine (internal standard). (D3) LC-MS chromatography of the
serum of one patient who had taken one capsule daily for three days before blood extraction.
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of resveratrol, quercetin, and catechin at different concentra-
tions where each significantly reduced cell proliferation and
blocked cell cycle progression in vitro. Also, other article
reported when polyphenols were fractionated and isolated,
the benefits of the whole extract were greater than the sum of
its parts, which indicated a synergism [19].
The results of this study showed that neither resvera-
trol nor its metabolites were detected in 10 out of 35 eyes.
Resveratrol and its metabolites could be detected in at
least the conjunctiva of 25 eyes. The concentrations of
resveratrol and its metabolites showed inter- and intraindi-
vidual variability. This feature is in line with previous
in vivo studies [17]. In our study, at least one of the three
metabolites could be quantified in the three different tissues.
It is clear that the concentrations also depend on the size and
volume of the tissues. The time span for obtaining samples
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403/113 resveratrol-4′-O-glucuronide 
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283/268 carbamazepine
Figure 4: The chromatograms and the related mass-to-charge ratio (m/z) of the total materials using chromatography combined
mass spectrometry.
Table 2: Concentrations of resveratrol and its major metabolites in the tissues of eyes.
Species
Mean± SD or N (%)
Conjunctiva (nmol/g) Aqueous humor (nmol/L) Vitreous humor (nmol/L)
Resveratrol
17.19± 15.32
(0.97–45.12) Bod Bod
n = 8
Resveratrol-3-O-glucuronide
2.32± 2.00 86.11± 30.76
(0.46–6.85) (58.44–119.24) Bod
n = 8 n = 3
Resveratrol-4′-O-glucuronide
2.12± 2.09 85.17± 56.73
(0.35–7.14) (14.40–148.46) Bod
n = 9 n = 4
Resveratrol-3-sulfate
22.31± 24.18 364.9± 523.94 62.95± 41.97
(1.20–76.65) (23.38–1503.76) (22.75–128.20)
n = 17 n = 7 n = 6
Note: values are the mean ± SD of the samples from 35 eyes. Range is in brackets. N, the number of samples which could be quantitated; Bod, below the
limit of detection.
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was also different, and this may also be a cause of the different
concentrations in different tissues. However, the real eva-
luation of the concentration of resveratrol in vivo is difficult.
Resveratrol could combine with lipoproteins or cell mem-
branes, so it appears to have low bioavailability.
The blood-ocular barrier contains the blood-retinal
barrier (BRB) and the blood-aqueous humor barrier (BAB).
The BAB is formed by endothelial cells of the blood vessels
in the iris and the nonpigmented cell layer of the ciliary epi-
thelium. The BRB is composed of retinal pigment epithelium
(RPE) and the tight retinal capillary wall. One study reported
that the BAB is less functional than the BRB in human eyes
and that the permeability of the BAB to hydrophilic sub-
stances is higher than that of the BRB [20]. Tsuboi et al. [21]
reported a significant increase in permeability across the
RPE in detached eyes with retinal tears. A similar situation
was reported by Cantrill and Pederson [22] in monkey eyes
with detached retinas. Retinal tears increase the permeability
of the BRB because of damage to the local physical structure
of the neurosensory retina, although the RPE layer is still
intact. The release of factors can influence local vascular
permeability in the anterior segment. Little et al. reported that
blood vessels in the iris and ciliary body of patients with
rhegmatogenous retinal detachment are much more perme-
able than those of normal controls [23]. In our experimental
results, the hydrophilic substances of resveratrol metabolites
were the main quantitative substances in the aqueous humor
and the vitreous humor. The most reasonable explanation
for this is that the resveratrol was quickly metabolized into
its three metabolites when orally administered. The metabo-
lites then entered the aqueous humor and vitreous humor,
especially the aqueous humor. Resveratrol and its metabolites
were higher in the conjunctiva. This may be the reason for
little residual blood in the conjunctival vessels. This result
could provide experimental support for the treatment of
ocular surface diseases [24]. The concentration of the parent
resveratrol and its three metabolites in the serum was higher
than that of the ocular tissues at an equivalent time point.
Resveratrol is firstly aborbed in the intestine and then enters
the systematic circulation and finally enters the eye. And the
blood can provide drugs for the eyes continuously.
4.1. Possible Biological Functions Associated with the
Concentration of Resveratrol. In our study, the concentration
of resveratrol and its metabolites was measured at the nM
level (nmol/L). The parent resveratrol could be quantified
only in the conjunctiva. The highest and average concentra-
tions were 45.12 nmol/g and 17.19 nmol/g, respectively. In
the aqueous humor and vitreous humor, the free resveratrol
was below or close to the limit of the detectable level at
10.96 nmol/L. The literature reveals that the concentration
of resveratrol in red wine is variable; for example, the
level in a moderate amount of red wine (300–600ml)
is ~2.4 nM and the concentration of the total equivalents
is ~180nM [25]. The long-term drinking of red wine is
considered beneficial for the human body because, in part, it
contains resveratrol; this has been demonstrated epide-
miologically and in in vitro and in vivo experiments. The
protective effect is established on the basis of dietary concen-
trations, which are always very low in vivo.
Pearce et al. found that resveratrol could activate telo-
merases at a concentration of 10−8M and could immortalize
mammary epithelial progenitors [26]. However, interestingly,
this only occurs at the lowest concentration. When the
concentration is increased at the micromolar level of resver-
atrol in certain cellular models, it may upregulate p53 by
increasing the cellular content and inducing posttranslational
modifications, resulting in senescence and apoptosis [26]. In
contrast, Waite et al. found that 0.1 nM resveratrol could
activate the PTEN protein to inhibit the proliferation of
breast cancer cells [27]. Another study reported that nano-
molar concentrations of resveratrol have cardiovascular
protective effects, including inhibition of platelet aggregation
[28]. Resveratrol exhibits a U- or J-shaped risk curve [16].
In conclusion, some experiments have reported opposite
results and further clinical research is needed to explore
the optimal concentration of resveratrol for the treatment
of human disease.
There only have been few studies to detect the concen-
tration of resveratrol in human tissues. Some reported that
resveratrol accumulates in the bile, stomach, liver, and
kidneys [29]. Many experiments have been done in vitro or
by using animal models associated with the eyes. Micromolar
concentrations of resveratrol inhibit the proliferation and
migration of blood vessel endothelial cells that are crucial
for angiogenesis [30, 31], protect against lens epithelial cell
apoptosis in diabetic cataracts in rats [32], protect against
inflammatory ocular surface diseases, such as dry eye disease
and severe allergies [24], and inhibit the proliferation of
retinoblastoma cells [3]. The nanomolar concentration of
resveratrol necessary for effective treatment of the human
eyes has not been demonstrated. Clinical drug trials are more
complicated than animal or in vitro experiments, as they
require more time, even years, for a treatment cycle. Many
reports have proved that resveratrol is beneficial to the
human eyes [16, 33]. This effect may be due to the long-
term or short-term effects associated with the expansion of
blood vessels in the eyes [34, 35], and other compounds in
Table 3: Concentrations of resveratrol and its major metabolites in the serum of three participants.
Species
Concentration (nmol/L)
Mean± SD or N (%)
Patient 1 Patient 2 Patient 3
Resveratrol 174.1 337.7 21.9 177.9
Resveratrol-3-O-glucuronide 54.5 162.9 481.7 233.0
Resveratrol-4′-O-glucuronide 44.6 155.4 456 218.7
Resveratrol-3-sulfate 257.6 2112 3539 1969.5
Note: the blood was drawn at about 2 hours after the final dose of resveratrol.
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the drug may have a synergistic effect with resveratrol.
One article reported that quercetin could inhibit resvera-
trol sulfate in the liver and duodenum [36], and it could
also enhance the resveratrol-induced reduction of inflam-
mation and oxidative stress in ocular surface epithelial
cells [24]. The Longevinex that we used in this experiment
was described in detail in our previous study [35]. Its main
ingredients are trans-resveratrol, quercetin, vitamin D, and
ferulic acid.
4.2. Concentration of Resveratrol’s Metabolites and
Physiological Significance In Vivo. In this study, the main
metabolite in the eye tissues was resveratrol-3-O-sulfate. In
the conjunctiva, aqueous humor, and vitreous humor, the
average concentrations of this metabolite were 22.31 nmol/g,
364.9 nmol/L, and 62.95 nmol/L, respectively. This is in
accordance with previous reports that resveratrol has a short
half-life (~8–14min) in the body and is then widely meta-
bolized [37, 38]. However, one study reported that parent
resveratrol was the main form in the organs and tissues
[39]. In our experiment, the metabolites, especially resvera-
trol-3-O-sulfate, were the main form in eye tissues. Overall,
these findings contrast with results obtained previously [39].
Schueller et al. reported that sulfated metabolites of the par-
ent resveratrol showed a beneficial potential for attenuating
inflammatory immune processes [40]. It is also important
to note that resveratrol metabolites were thought of as the
pool of the parent resveratrol [8], so there was an assumption
that the resveratrol metabolites may perform certain activi-
ties or transform into parent resveratrol to have a beneficial
effect in organs and tissues. With only three days of adminis-
tration, reservatrol and its metabolites could still be detected
throughout the eye.
Many articles provide evidence that resveratrol’s biologi-
cal activities include vasorelaxant activity, antiangiogenesis
activity, anti-inflammatory activity, antioxidant activity, and
so on through different molecular mechanisms using animal
models and in vitro retinal cells [3, 25, 41]. It is clear that res-
veratrol may have potential in the treatment of several ocular
diseases, such as primary open-angle glaucoma (POAG) [42],
age-related macular degeneration (AMD) [3], diabetic reti-
nopathy (DR) [3], and even ocular tumors [43]. In light of
the current interest in resveratrol as a potential preventive
and therapeutic agent, we hope that our results, measuring
resveratrol levels and its metabolites in the human eye, will
help define doses that may be used in future treatment and
in the prevention of ocular disease.
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